Class IITerminatedD-0196-2023
Drug recall · February 1, 2023
Buprenorphine HCL 0.9 MG/ML recall
Why: Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Buprenorphine HCL 0.9 MG/ML (25ML vial) Injectable, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Lots / codes
t20221118@33
- Quantity
- N/A
- Company
- Pharmacy Innovations, Erie, PA
- Distribution
- Nationwide in the USA
- Initiated
- December 22, 2022 · Voluntary: Firm initiated
- Classified
- January 26, 2023
- Reported
- February 1, 2023
- Ended
- July 31, 2024
- How notified
- Telephone
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Class IITerminatedFeb 1, 2023Dutasteride 0.1%Pharmacy Innovations · D-0185-2023Class IITerminatedFeb 1, 2023Chlorpheniramine/HyoscyaminePharmacy Innovations · D-0186-2023Class IITerminatedFeb 1, 2023Hydroxocobalamin 25MG/MLPharmacy Innovations · D-0187-2023Class IITerminatedFeb 1, 2023Methylcobalamin 1MG/MLPharmacy Innovations · D-0188-2023Class IITerminatedFeb 1, 2023Minoxidil 0.75%Pharmacy Innovations · D-0189-2023Class IITerminatedFeb 1, 20235-Fluorouracil 1%Pharmacy Innovations · D-0190-2023Class IITerminatedFeb 1, 2023Acetylcysteine 10% Ophthalmic SolutionPharmacy Innovations · D-0191-2023Class IITerminatedFeb 1, 2023AlbuterolPharmacy Innovations · D-0192-2023Class IITerminatedFeb 1, 2023Apomorphine HCL 2MG/MLPharmacy Innovations · D-0193-2023Class IITerminatedFeb 1, 2023Atropine sulfate 0.05%Pharmacy Innovations · D-0194-2023Class IITerminatedFeb 1, 2023BSS Plus/Lidocaine Opth 1%Pharmacy Innovations · D-0195-2023Class IITerminatedFeb 1, 2023Ceftazidime IntravitrealPharmacy Innovations · D-0197-2023
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Buprenorphine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.